CpG motif-based adjuvant as a replacement for Freund's complete adjuvant in a recombinant LHRH vaccine

Conforti, Valéria Amorim; Avila, David M. de; Cummings, Nada S.; Zanella, Ricardo; Wells, K. J.; Ülker, Hasan; Reeves, Jerry J.

doi:10.1016/j.vaccine.2007.12.010

Cited by 20 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 Based on serial evaluation of serum progestagen concentrations and GnRH antibody titers, 3 additional boosters of increasing dosage (7.5 mg on 29 November 2007, 8 mo after initial injection; 12.5 mg on 27 March 2008, 12 mo after the initial injection; 30 mg on 20 November 2008, 20 mo after the initial injection) were given. The total injection volume increased from 4.5 to 22 ml, with increases in dosage; the volume of each dose was divided in two and administered s.c. by hand injection at two sites on the neck.…”

Section: Methodsmentioning

confidence: 99%

“…23,46 The vaccine in this study was developed by using a recombinant ovalbuminGnRH fusion protein, marketed under the trade name Repro-BLOCt (Amplicon Vaccine, LLC, Pullman, Washington 99163, USA). 11,20,33,51,56 The adjuvant is a combination of Freund's incomplete adjuvant with a synthetic cytosine guanine oligodeoxynucleotide that mimics the immunostimulatory effects of bacterial deoxyribonucleic acid because of its relatively high content of unmethylated cytosine guanine dinucleotides. 10,11 This case report describes the use of Repro-BLOC to suppress ovarian cyclicity to prevent hemorrhage and anemia associated with reproductive tract pathologies in an older female Asian elephant at the National Zoological Park.…”

Section: Introductionmentioning

confidence: 99%

“…11,20,33,51,56 The adjuvant is a combination of Freund's incomplete adjuvant with a synthetic cytosine guanine oligodeoxynucleotide that mimics the immunostimulatory effects of bacterial deoxyribonucleic acid because of its relatively high content of unmethylated cytosine guanine dinucleotides. 10,11 This case report describes the use of Repro-BLOC to suppress ovarian cyclicity to prevent hemorrhage and anemia associated with reproductive tract pathologies in an older female Asian elephant at the National Zoological Park. To date, to the authors' knowledge, there are no published reports on the use of GnRH vaccination to control reproductive activity in female elephants.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

EFFECTS OF A GONADOTROPIN-RELEASING HORMONE VACCINE ON OVARIAN CYCLICITY AND UTERINE MORPHOLOGY OF AN ASIAN ELEPHANT (ELEPHAS MAXIMUS)

Boedeker¹,

Hayek²,

Murray³

et al. 2012

Journal of Zoo and Wildlife Medicine

Self Cite

View full text Add to dashboard Cite

This report describes the successful use of a gonadotropin-releasing hormone (GnRH) vaccine to suppress ovarian steroidogenic activity and to treat hemorrhage and anemia associated with reproductive tract pathology in a 59-year-old Asian elephant (Elephas maximus). The Repro-BLOCt GnRH vaccine was administered subcutaneously as a series of 4 boosters of increasing dose from 3 to 30 mg of recombinant ovalbumin-GnRH fusion protein given at variable intervals after initial vaccination with 3 mg protein. Efficacy was confirmed over a year after initial vaccination based on complete ovarian cycle suppression determined by serum progestagen analyses. Estrous cycle suppression was associated with a significant increase in GnRH antibody binding and subsequent decrease in serum luteinizing hormone and follicle-stimulating hormone concentrations. Ultrasonographic examinations of the reproductive tract documented a reduction in uterine size and vascularity after immunization. The hematocrit level normalized soon after the initial intrauterine hemorrhage, and no recurrence of anemia has been detected. No substantive adverse effects were associated with GnRH vaccination. The results indicate that GnRH vaccination in elephants shows potential for contraception and management of uterine pathology in older elephants.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

EFFECTS OF A GONADOTROPIN-RELEASING HORMONE VACCINE ON OVARIAN CYCLICITY AND UTERINE MORPHOLOGY OF AN ASIAN ELEPHANT (ELEPHAS MAXIMUS)

Boedeker¹,

Hayek²,

Murray³

et al. 2012

Journal of Zoo and Wildlife Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, no significant decrease in testis weight and minimal anti-GnRH antibody response was observed in the same study when male piglets were treated with GnRH lipo-amide incorporated in ISCOMs [30]. Only a few studies [31,32] have induced an anti-GnRH immune response and gonadal regression in the absence of Freund's adjuvants. Conforti et al [31] reported CpG ODN 2006 as an efficient replacement of FCA for a recombinant LHRH-ovalbumin fusion protein antigen.…”

Section: Discussionmentioning

confidence: 89%

“…Only a few studies [31,32] have induced an anti-GnRH immune response and gonadal regression in the absence of Freund's adjuvants. Conforti et al [31] reported CpG ODN 2006 as an efficient replacement of FCA for a recombinant LHRH-ovalbumin fusion protein antigen. Vaccine treatments using various doses of the antigen emulsified with CpG ODN 2006 in mineral oil caused gonadal regression and estrus suppression in heifers.…”

Section: Discussionmentioning

confidence: 99%

Parenteral administration of GnRH constructs and adjuvants: Immune responses and effects on reproductive tissues of male mice

Sharma

McDonald

Miller³

et al. 2014

Vaccine

View full text Add to dashboard Cite

a b s t r a c tTwo gonadotrophin releasing hormone (GnRH) constructs prepared by either chemical conjugation to keyhole limpet hemocyanin (GnRH-KLH) or as an expressed recombinant fusion protein (Multimer) were evaluated with or without adjuvants (immunostimulating complexes, ISCOMs, or cytosine-phosphateguanosine oligodeoxynucleotides, CpG ODNs). After subcutaneous administration to Balb/c male mice at Weeks 0, 2 and 4, these preparations were assessed for induction of immune responses and effects on reproductive organs. GnRH-KLH plus ISCOMs formulation induced strong IgG immune responses from Week 4 through Week 12 resulting in consistent reproductive organ atrophy by Week 12 after subcutaneous administration. GnRH-KLH plus CpG ODNs generated immune responses but no atrophy of reproductive tissues by Week 12. Multimer plus ISCOMs induced poor immune responses and no effects on reproductive tissues by Week 12. In the absence of additional adjuvant, none of the GnRH constructs induced reproductive organ atrophy. GnRH-KLH induced stronger immune responses when formulated with ISCOMs or CpG ODN compared to Multimer. GnRH-KLH with ISCOMs could be an effective colloidal alternative for emulsion GnRH vaccine formulations.

show abstract

Selection of Optimal Adjuvants and Product Factors that Affect Vaccine Immunogenicity

Wang

Singh

2011

Development of Vaccines

View full text Add to dashboard Cite

CpG motif-based adjuvant as a replacement for Freund's complete adjuvant in a recombinant LHRH vaccine

Cited by 20 publications

References 20 publications

EFFECTS OF A GONADOTROPIN-RELEASING HORMONE VACCINE ON OVARIAN CYCLICITY AND UTERINE MORPHOLOGY OF AN ASIAN ELEPHANT (ELEPHAS MAXIMUS)

EFFECTS OF A GONADOTROPIN-RELEASING HORMONE VACCINE ON OVARIAN CYCLICITY AND UTERINE MORPHOLOGY OF AN ASIAN ELEPHANT (ELEPHAS MAXIMUS)

Parenteral administration of GnRH constructs and adjuvants: Immune responses and effects on reproductive tissues of male mice

Selection of Optimal Adjuvants and Product Factors that Affect Vaccine Immunogenicity

Contact Info

Product

Resources

About